Imugene’s Blood Cancer Drug Hits 71% Response Rate in Hard-to-Treat BTKi Patients [VIDEO]
Imugene's azer-cel BTKi trial results show a 71% overall response rate across seven evaluable patients in Cohort 3 — including a complete response in Mantle Cell Lymphoma — bringing the full Phase 1b dataset to a 75% ORR across 55 patients.
Key Takeaways
- Four additional patients in Cohort 3 of Imugene's azer-cel Phase 1b trial have reached their Day 28 assessment, with two responding — one Complete Response in MCL and one Partial Response in CLL.
- The BTKi combination cohort now has seven evaluable patients and a 71% Overall Response Rate, with all patients having previously relapsed on or become refractory to BTKi therapy.
- Across the full Phase 1b dataset of 55 evaluated patients spanning three cohorts, azer-cel has achieved a combined 75% ORR, with Cohort 2 (CAR T-naïve) leading at 81%.
- The global BTKi market exceeded US$12.0 billion in 2025, underscoring the commercial scale of the patient population azer-cel's Cohort 3 is targeting.
- Enrolment remains ongoing across 15 trial sites — 10 in the United States and 5 in Australia — with further clinical updates expected as data matures.
![FirstWave Cloud Technology Cuts FY26 Loss 80% With Second Year of Positive Cash Flow [VIDEO]](https://media.stockwirex.com/server-room-display.jpg)
![Syntara Expands Scar Drug Trial to 30 Patients With Results Due Q1 2027 [VIDEO]](https://media.stockwirex.com/lab_research_desk.jpg)
![Genetic Signatures Agrees Merger With Microba to Build $30M Revenue Diagnostics Group [VIDEO]](https://media.stockwirex.com/GSS-Lab-Interior.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer